Focus: Rain Oncology is a publicly-traded small-molecule oncology biotech founded in 2022, headquartered in Newark, CA, with a focused pipeline in solid tumors and hematologic malignancies. The company operates at early-to-mid clinical stage with nine active trials across Phase 1-3.
Profile data last refreshed 14h ago · AI intelligence enriched 1w ago
Cooling — net -6 jobs in 30d
4 added, 10 removed. Slower than typical.
Rain Oncology is a speculative early-stage oncology play with Phase 3 optionality but no revenue, limited public disclosure, and disproportionate IT hiring that suggests execution risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Rain Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rain Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo